Callisto Pharmaceuticals Inc. is a drug development company focused on the clinical development of drugs to treat cancer. The company's most advanced drug candidate is Annamycin, an anthracycline for the treatment of relapsed leukemias. Callisto's other products being developed include Atiprimod, for relapsed multiple myeloma and bone resorption.
420 Lexington Avenue
New York, NY 10170